FCOMV
ACET icon

Foresite Capital Opportunity Management V’s Adicet Bio ACET Stock Holding History

Foresite Capital Opportunity Management V’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2.42M Hold
10,625
– – 7.26% 6
2022
Q2 		$2.48M Hold
10,625
– – 6.26% 6
2022
Q1 		$3.4M Hold
10,625
– – 4.75% 6
2021
Q4 		$2.97M Buy
+10,625
New +$1.82M 1.99% 9

Other funds holding ACET

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Foresite Capital Opportunity Management V's ACET Position: Q3 2022 in Review

Foresite Capital Opportunity Management V held its Adicet Bio (ACET) position steady in Q3 2022 at 10,625 shares worth $2.42M. The position accounts for 7.26% of the portfolio, ranked #6.

Foresite Capital Opportunity Management V first reported a position in ACET in Q4 2021 and has held it in 4 quarters since. The position peaked at $3.4M in Q1 2022. 102 funds tracked by Wall St. Rank hold ACET as of Q3 2022.

  • Foresite Capital Opportunity Management V held 10,625 shares of Adicet Bio worth $2.42M as of Q3 2022.
  • Foresite Capital Opportunity Management V left its Adicet Bio share count unchanged in Q3 2022.
  • Adicet Bio made up 7.26% of Foresite Capital Opportunity Management V's portfolio in Q3 2022, its #6 holding.
  • Foresite Capital Opportunity Management V first reported a position in Adicet Bio in Q4 2021 and has held it in 4 quarters since.
  • Foresite Capital Opportunity Management V's Adicet Bio position peaked at $3.4M in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2022.

Based on Foresite Capital Opportunity Management V's 13F filing for Q3 2022, filed 14 Nov 2022.